GeNeuro | BUY - TP EUR6 | Fighting the aliens inside us
Fighting the aliens inside usA game-changing opportunity on the horizon…
Having faced numerous setbacks in the past, including inconclusive Phase II data in their multiple sclerosis (MS) program that were not robust enough to confidently move their drug forward in a pivotal phase III trial and secure a deal with a large pharmaceutical company, GeNeuro’s next Phase IIb ProTect-MS will give the company its last opportunity to go for the double.
Maintenance of our EUR6 TP
Our TP stands still at EUR6/share with the MS program being the only valuable asset in our model. We are still putting no value on any other project in development. Also, we have applied a PoS of 45% that the drug will reach the market and applied PoS of 60% that GeNeuro will effectively sign a deal with a pharma company. Cash outreach is Q4 22.
GeNeuro SA. Geneuro SA is a Switzerland-based clinical stage pharmaceutical company that develops treatments for autoimmune diseases, including multiple sclerosis (MS) and other diseases associated with human endogenous retroviruses (HERV). The Company's main product, GNbAC1, is a humanized monoclonal antibody that is in clinical development phase IIb. GNbAC1 neutralizes the MSRV-Env protein rather than targeting the patient's immune system, and slows down or even halts the progression of multiple sclerosis. The Company's main shareholders are Eclosion2, a launching platform for new companies in the life sciences field, bioMerieux SA, which specializes in vitro diagnostics for medical and industrial applications, Institut Merieux, a private equity company, and Servier, an independent French pharmaceutical company.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.